SHB-04-CD22

SHB-04-CD22 is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target CD22, a cell surface antigen highly expressed on B-cell malignancies. The therapy is prepared by genetically engineering a patient's own T cells to express an anti-CD22 chimeric antigen receptor, enabling them to selectively recognize and eliminate CD22-positive cancer cells. It is currently being evaluated in a Phase 1/2 clinical trial in Israel for the treatment of relapsed or refractory CD22-expressing B-cell malignancies, including acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia, particularly in patients who have failed standard therapies or prior CD19-directed CAR-T cell treatments.

Other names

CD22 CAR-TCD-22 CAR-TCD 22 CAR-Tanti-CD22 CAR-expressing T lymphocytesanti-CD-22 CAR-expressing T lymphocytesanti-CD 22 CAR-expressing T lymphocytes